Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (18) 18
humans (14) 14
life sciences & biomedicine (14) 14
animals (10) 10
potent (9) 9
cancer (7) 7
pharmacology & pharmacy (6) 6
physical sciences (6) 6
antineoplastic agents - therapeutic use (5) 5
chemistry (5) 5
oncology (5) 5
antineoplastic agents - pharmacology (4) 4
cell line, tumor (4) 4
clinical trials as topic (4) 4
drug delivery (4) 4
drugs (4) 4
female (4) 4
potent antitumor-activity (4) 4
tumors (4) 4
apoptosis (3) 3
biological and medical sciences (3) 3
chemistry, medicinal (3) 3
chemistry, multidisciplinary (3) 3
clinical trials (3) 3
cytotoxicity (3) 3
drug delivery systems (3) 3
mice (3) 3
neoplasms - drug therapy (3) 3
potent anticancer activity (3) 3
proteins (3) 3
structure-activity relationship (3) 3
therapy (3) 3
activation (2) 2
analogs (2) 2
antitumor (2) 2
binding sites (2) 2
biochemistry & molecular biology (2) 2
biotechnology (2) 2
cancer therapies (2) 2
care and treatment (2) 2
chemotherapy (2) 2
colonic neoplasms - metabolism (2) 2
combination (2) 2
cyclin-dependent kinases - antagonists & inhibitors (2) 2
cyclin-dependent kinases - metabolism (2) 2
cytotoxic (2) 2
doxorubicin - analogs & derivatives (2) 2
drug delivery systems - methods (2) 2
drug design (2) 2
drug development (2) 2
drug discovery (2) 2
genetic therapy (2) 2
growth-factor receptor (2) 2
immunology (2) 2
in-vitro (2) 2
in-vivo (2) 2
life sciences (2) 2
materials science (2) 2
medical sciences (2) 2
molecular targeted therapy (2) 2
mutation (2) 2
necrosis-factor-alpha (2) 2
neoplasm staging (2) 2
neoplasms - pathology (2) 2
novel (2) 2
peptides (2) 2
pharmacokinetics (2) 2
pharmacology. drug treatments (2) 2
potent cytotoxicity (2) 2
protein kinase inhibitors - pharmacology (2) 2
review (2) 2
rna, small interfering - metabolism (2) 2
science & technology - other topics (2) 2
side effects (2) 2
signal transduction - drug effects (2) 2
synthesis (2) 2
technology (2) 2
tumor necrosis factor-alpha - metabolism (2) 2
umcg approved (2) 2
valproic acid (2) 2
vehicles (2) 2
2-pyrollinodoxorubicin (1) 1
3-kinase/akt signaling pathway (1) 1
[info.info-bt]computer science [cs]/biotechnology (1) 1
[sdv.imm.imm] life sciences [q-bio]/immunology/immunotherapy (1) 1
[sdv.imm]life sciences [q-bio]/immunology (1) 1
[sdv] life sciences [q-bio] (1) 1
acetyltransferases - antagonists & inhibitors (1) 1
acetyltransferases - genetics (1) 1
acetyltransferases - metabolism (1) 1
acids (1) 1
acquired-resistance (1) 1
activity (1) 1
acute myeloid-leukemia (1) 1
administration, oral (1) 1
adult (1) 1
advanced solid tumors (1) 1
aged (1) 1
agents (1) 1
albumin-based nanoparticle paclitaxel-snapist trials (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
by Weekes, Colin D and Lamberts, Laetitia E and Borad, Mitesh J and Voortman, Johannes and McWilliams, Robert R and Diamond, Jennifer R and de Vries, Elisabeth G. E and Verheul, Henk M and Lieu, Christopher H and Kim, George P and Wang, Yulei and Scales, Suzie J and Samineni, Divya and Brunstein, Flavia and Choi, YounJeong and Maslyar, Daniel J and Colon-Otero, Gerardo
Molecular cancer therapeutics, ISSN 1535-7163, 03/2016, Volume 15, Issue 3, pp. 439 - 447
AURISTATIN-E CONJUGATE | DIAGNOSIS | POTENT | MARKER | CARCINOMAS | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | EXPRESSION | BINDING | CHEMOTHERAPY | Life Sciences & Biomedicine | Oncology | Science & Technology | Immunohistochemistry | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Immunoconjugates - pharmacology | Immunoconjugates - therapeutic use | Adult | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | GPI-Linked Proteins - antagonists & inhibitors | Ovarian Neoplasms - drug therapy | Platinum - therapeutic use | Drug Administration Schedule | Treatment Outcome | Disease Progression | Retreatment | Biomarkers | Aged | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Heat shock protein antagonists in early stage clinical trials for NSCLC
by Hendriks, Lizza E.L and Dingemans, Anne-Marie C
Expert opinion on investigational drugs, ISSN 1354-3784, 05/2017, Volume 26, Issue 5, pp. 541 - 550
Early clinical trials | non-small cell lung cancer | Hsp70 inhibitors | Hsp90 inhibitors | Hsp27 inhibitors | ADVANCED SOLID TUMORS | ACQUIRED-RESISTANCE | HSP90 INHIBITOR GANETESPIB | I DOSE-ESCALATION | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | POTENT ANTITUMOR-ACTIVITY | GROWTH-FACTOR RECEPTOR | OCULAR TOXICITY | PHASE-I | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | HSP70 Heat-Shock Proteins - antagonists & inhibitors | Humans | Heat-Shock Proteins - antagonists & inhibitors | Lung Neoplasms - pathology | Patient Selection | Animals | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Drug Design | Antineoplastic Agents - pharmacology | HSP27 Heat-Shock Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
by de Groot, Jan Willem B and Links, Thera P and Plukker, John T. M and Lips, Cornelis J. M and Hofstra, Robert M. W
Endocrine reviews, ISSN 0163-769X, 08/2006, Volume 27, Issue 5, pp. 535 - 560
PROTOONCOGENE POINT MUTATIONS | POTENT ANTITUMOR-ACTIVITY | MEDULLARY-THYROID-CARCINOMA | GROWTH-FACTOR RECEPTOR | CODON 918 MUTATION | GERMLINE-SEQUENCE VARIANTS | NEOPLASIA TYPE 2A | FOCAL-ADHESION KINASE | 3-KINASE/AKT SIGNALING PATHWAY | UMCG Approved | RECEPTOR TYROSINE KINASE | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Fundamental and applied biological sciences. Psychology | Vertebrates: endocrinology | Biological and medical sciences | Haplotypes | Gene Targeting | Genetic Therapy | Multiple Endocrine Neoplasia Type 2a - diagnosis | Endocrine Gland Neoplasms - genetics | Humans | Polymorphism, Genetic | Endocrine Gland Neoplasms - therapy | Animals | Proto-Oncogene Proteins c-ret - physiology | Signal Transduction - drug effects | Models, Biological | Endocrine Gland Neoplasms - diagnosis | Ligands | Multiple Endocrine Neoplasia Type 2a - therapy | Fetal Development - genetics | Multiple Endocrine Neoplasia Type 2a - genetics | Proto-Oncogene Proteins c-ret - antagonists & inhibitors | Proto-Oncogene Proteins c-ret - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
by Temming, Kai and Schiffelers, Raymond M and Molema, Grietje and Kok, Robbert J
Drug resistance updates, ISSN 1368-7646, 2005, Volume 8, Issue 6, pp. 381 - 402
Therapeutic proteins | Angiogenesis | Gene delivery | Arg-Gly-Asp | Drug delivery | Antivascular therapies | Polymers | Radiotracer | RGD | Endothelial cells | Cytostatic drugs | Cancer | endothelial cells | VITRONECTIN RECEPTOR ANTAGONIST | SNAKE-VENOM DISINTEGRINS | angiogenesis | NECROSIS-FACTOR-ALPHA | drug delivery | UMCG Approved | therapeutic proteins | CANCER ALPHA(V)-INTEGRIN EXPRESSION | gene delivery | POTENT ANTITUMOR-ACTIVITY | CONDITIONALLY REPLICATIVE ADENOVIRUSES | POSITRON-EMISSION-TOMOGRAPHY | radiotracer | cytostatic drugs | ALPHA(V)BETA INTEGRIN ANTAGONISTS | VIRUS-LIKE PARTICLES | cancer | antivascular therapies | polymers | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Neoplasms - metabolism | Recombinant Proteins - therapeutic use | Tumor Necrosis Factor-alpha - metabolism | Doxorubicin - therapeutic use | Genetic Therapy | RNA, Small Interfering - genetics | Humans | Tumor Necrosis Factor-alpha - genetics | Antineoplastic Agents - therapeutic use | Neoplasms - diagnosis | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - genetics | Drug Carriers - chemistry | Integrin alphaVbeta3 - metabolism | Peptides, Cyclic - metabolism | Oligopeptides - therapeutic use | Antineoplastic Agents - metabolism | Transfection | Neoplasms - genetics | Doxorubicin - analogs & derivatives | Doxorubicin - metabolism | Oligopeptides - chemistry | Polyethylene Glycols - metabolism | Recombinant Proteins - metabolism | Endothelial Cells - metabolism | Oligopeptides - genetics | Genetic Vectors - metabolism | Clinical Trials as Topic | Oligopeptides - metabolism | Genetic Vectors - genetics | Neoplasms - drug therapy | Integrin alphaVbeta3 - analysis | Tumor Necrosis Factor-alpha - therapeutic use | Animals | Mutation | RNA, Small Interfering - metabolism | Proteins | Drugs | Drug delivery systems | Care and treatment | Peptides | Radioactive tracers | Health aspects | Tumors | Vehicles | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
by Wanda DePinto and Xin-Jie Chu and Xuefeng Yin and Melissa Smith and Kathryn Packman and Petra Goelzer and Allen Lovey and Yingsi Chen and Hong Qian and Rachid Hamid and Qing Xiang and Christian Tovar and Roger Blain and Tom Nevins and Brian Higgins and Leopoldo Luistro and Kenneth Kolinsky and Bernardo Felix and Sazzad Hussain and David Heimbrook
Molecular Cancer Therapeutics, ISSN 1535-7163, 11/2006, Volume 5, Issue 11, pp. 2644 - 2658
potent in vitro and in vivo preclinical antitumor activity | in phase I clinical trials | CDK selective inhibitor | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclin-Dependent Kinases - metabolism | Humans | Rats, Inbred F344 | Retinoblastoma - drug therapy | Antineoplastic Agents - therapeutic use | G1 Phase - drug effects | G2 Phase - drug effects | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cyclin-Dependent Kinases - antagonists & inhibitors | Genes, MDR - drug effects | Phosphorylation - drug effects | Tumor Suppressor Protein p53 - metabolism | Rats | Pyrimidines - pharmacology | Retinoblastoma - metabolism | Animals | Mice, Nude | Pyrimidines - therapeutic use | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Cell Proliferation - drug effects | Mice | Clinical Trials, Phase I as Topic | Apoptosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Synthesis and antitumor activity of non-prodrug water-soluble taxoid: 10-C-aminoalkylated docetaxel analogs
by Iimura, Shin and Ohsuki, Satoru and Chiba, Jun and Uoto, Kouichi and Iwahana, Michio and Terasawa, Hirofumi and Soga, Tsunehiko
Heterocycles, ISSN 0385-5414, 12/2000, Volume 53, Issue 12, pp. 2719 - 2737
Journal Article
Details down arrow
7. Full Text Discovery of AZD1152: A Selective Inhibitor of Aurora‐B Kinase with Potent Antitumor Activity
by Foote, Kevin M and Mortlock, Andrew A
10/2009, ISBN 0470278293, 24
AZD 1152 discovery ‐ selective inhibitor of Aurora‐B kinase with potent antitumor activity | quinazolines substituted with aminothiazoles | screening cascade updated | AZD 1152 discovery-selective inhibitor of Aurora-B kinase with potent antitumor activity | Quinazolines substituted with aminothiazoles | Screening cascade updated
Book Chapter
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Modified silica nanoparticles with an aminonaphthoquinone
by Silveira, Gleiciani Q and Ronconi, Célia M and Vargas, Maria D and Gil, Rosane A. S. San and Magalhães, Alvicler
Journal of the Brazilian Chemical Society, ISSN 0103-5053, 2011, Volume 22, Issue 5, pp. 961 - 967
Silica nanoparticles | Naphthoquinones | Multifunctional material | Physical Sciences | Chemistry | Chemistry, Multidisciplinary | Science & Technology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights